Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24114648 | 0.81 | HSD17B10 (0.68) | HSD17B10HPGDHTTPDE4BADORA2A | |
| SCHEMBL10495854 | 0.80 | HSD17B10 (0.67) | HSD17B10HPGDHTTPDE4BATAD2 | |
| SCHEMBL20129910 | 0.80 | HSD17B10 (0.65) | HSD17B10ADORA2B | |
| SCHEMBL31008678 | 0.80 | HSD17B10 (0.65) | HSD17B10ADORA2B | |
| SCHEMBL19657540 | 0.78 | HSD17B10 (0.65) | HSD17B10HPGDHTTATAD2PDE3B | |
| SCHEMBL13521745 | 0.78 | HSD17B10 (0.63) | HSD17B10HPGDHTTPDE4BPDE3B | |
| SCHEMBL19020217 | 0.77 | HSD17B10 (0.61) | HSD17B10HPGDHTTADORA3ADORA2B | |
| Lithium Ion SCHEMBL30176719 | 0.77 | HSD17B10 (0.61) | HSD17B10 | |
| SCHEMBL25407471 | 0.77 | HSD17B10 (0.62) | HSD17B10HPGDHTTPDE4BATAD2 | |
| SCHEMBL30349792 | 0.77 | HSD17B10 (0.62) | HSD17B10HPGDHTTPDE4BATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-5002944-A | Compounds having cardiotonic activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0333727-A1 | HETEROCYCLIC SUBSTITUTED BICYCLOUREAS HAVING CARDIOTONIC ACTIVITY | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4859672-A | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone | RORER PHARMACEUTICAL CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| WO-1988003025-A1 | HETEROCYCLIC SUBSTITUTED BICYCLOUREAS HAVING CARDIOTONIC ACTIVITY | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HSD17B10 2143/4885HPGD 2639/4885HTT 1605/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HSD17B10 2143/4885HPGD 2639/4885HTT 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.